The Role of CMAs in Quality by Design (QbD): Quality cannot be tested into a product. It must be designed into it. In the QbD paradigm, Critical Material Attributes (CMAs) are the variables that determine whether that design holds or collapses when raw materials arrive at your dock.
CMA vs. CQA: Understanding the Difference in Pharmaceutical Technology Transfer: Conflating input material attributes with output product characteristics is a quiet but persistent source of scale-up failure.
Is Science the true starting point for innovation? Discover why the linear model is failing and how the dynamic cycle of Manufacturing, Science, and Technology Transfer is the real engine of progress.
Risk Evaluation in Biopharmaceutical Technology Transfer: Why a Risk-Based Approach Is Essential for GMP Success. Successful biopharmaceutical technology transfer depends on more than process knowledge.
Tagged : Biopharmaceutical, Compliance, GxP, MSAT, QRM, Quality 4.0, Risk Management, Technology Transfer
Navigating the Pitfalls of MSAT for Successful Technology Transfer: In the biopharmaceutical sector, MS&T responsibilities extend to both upstream and downstream processes. This includes optimizing cell culture conditions, managing bioreactor performance, and ensuring effective purification